Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	CA: a cancer journal for clinicians Ročník 62; číslo 6; s. 394 - 399
Hlavní autoři:	Maluccio, Mary, Covey, Anne
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2012 Wiley Subscription Services, Inc
Témata:	Ablation Techniques Algorithms Benzenesulfonates - therapeutic use Cancer Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic decision‐making/patient preferences Embolization, Therapeutic - methods Humans liver neoplasms Liver Neoplasms - diagnosis Liver Neoplasms - therapy Liver Transplantation Medical diagnosis Medical treatment Niacinamide - analogs & derivatives Phenylurea Compounds Protein Kinase Inhibitors - therapeutic use Pyridines - therapeutic use Radiosurgery
ISSN:	0007-9235, 1542-4863, 1542-4863
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient‐related variables such as comorbid conditions that influence treatment eligibility; 2) liver‐related variables such as Child‐Pugh score; and 3) tumor‐related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society.
Bibliografie:	The authors report no conflicts of interest. DISCLOSURES SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0007-9235 1542-4863 1542-4863
DOI:	10.3322/caac.21161